Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2309-2319

  Zhang, Yixian ^a   Castaneda, Stephen ^a   Dumble, Melissa ^a   Wang, Maoliang ^a   Mileski, Mary ^a   Qu, Zhengxing ^a   Kim, Steven ^a   Shi, Victoria ^a   Kraft, Patricia ^a   Gao, Ying ^a   Pak, Jenny ^a   Sapra, Puja ^a,c   Bandaru, Raj ^a   Zhao, Hong ^a   Vessella, Robert L ^b   Horak, Ivan D ^a,d   Greenberger, Lee M ^a  

^a Enzon Incorporated   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d Symphogne A/S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; EZN 4176; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; ARTICLE; BONE METASTASIS; CANCER INHIBITION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TREATMENT FAILURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355163334     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0329     Document Type: Article

References (55)

1. American Cancer Society. Cancer facts and figures, 2010. Atlanta, GA: American Cancer Society; 2010.
2. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
3. Zelefsky M, Eastham J, Sarto O, Kantoff PW. Cancer of the prostate. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 8th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008. p. 1393-452.
4. Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. Amulticenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-52.
5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
6. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-8.
7. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
8. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
9. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
10. Frieden M, Hansen HF, Koch T. Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids 2003;22:1041-3. (Pubitemid 37139318)
11. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010;38:e3.
12. Zhang Y, Qu Z, Kim S, Shi V, Liao B, Kraft P, et al. Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 2011;18: 326-33.
13. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008;7:3598-608.
14. Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM, Horak ID. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids 2010;29:97-112.
15. Elmen J, LindowM, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-9. (Pubitemid 351550859)
16. Lanford RE, Evans MJ, Lohmann V, Lindenbach B, Gale M Jr, Rehermann B, et al. The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus And Related Viruses. Gastroenterology 2009;136:9-16.
17. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, ChuTM, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18. (Pubitemid 13122588)
18. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-6.
19. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999;59: 4180-4. (Pubitemid 29418721)
20. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81. (Pubitemid 24173741)
21. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003;55:239-46. (Pubitemid 36618182)
22. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999;39:246-61. (Pubitemid 29244499)
23. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008;7:2736-45.
24. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009;19:89-102.
25. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997;94:10833-7.
26. Richardt-Pargmann D, Vollmer J. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors. Ann N Y Acad Sci 2009;1175:40-54.
27. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17:535-46.
28. Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR, Bozec A, et al. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One 2007;2:e1006.
29. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002;9:117-25. (Pubitemid 34141913)
30. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005;96:251-8. (Pubitemid 41080506)
31. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, et al. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 2004;172:1140-4. (Pubitemid 39096488)
32. Muraoka-Cook RS, Garrett J, Sanchez VK, Stanford JC, Young C, Chakrabarty A, et al. ErbB3 ablation impairs phosphatidylinositol 3-kinase (PI3K)/AKT-dependent mammary tumorigenesis. Cancer Res 2011;71:3941-51.
33. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
34. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al.A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
35. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
36. WatsonPA, Chen YF, Balbas MD,Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
37. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
38. Zhang Y, Dumble M, Castaneda S, Mileski M, Kim S, Qu Z, et al. Dual inhibition of the androgen receptor by ligand blockade and antisense-mediated downregulation is associated with synergistic antitumor activity model of prostate cancer [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2010 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; 2011. p 456. Abstract nr 5394.
39. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38. (Pubitemid 37163836)
40. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-31. (Pubitemid 27081674)
41. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer 2010;1: 617-28.
42. Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 1998;101:53-7. (Pubitemid 28071360)
43. Howell SB. DNA microarrays for analysis of gene expression. Mol Urol 1999;3:295-300.
44. Vaarala MH, Porvari K, Kyllonen A, Vihko P. Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 2000;80:1259-68. (Pubitemid 30637066)
45. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000;60:6134-41.
46. Elek J, Park KH, Narayanan R. Microarray-based expression profiling in prostate tumors. In Vivo 2000;14:173-82. (Pubitemid 30189227)
47. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20:6718-23. (Pubitemid 33020600)
48. Chaib H, Cockrell EK, Rubin MA, Macoska JA. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 2001;3:43-52. (Pubitemid 32201609)
49. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002;99:11890-5. (Pubitemid 34994494)
50. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, McLeod DG, et al. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 2001;92:322-8. (Pubitemid 32249705)
51. Waghray A, Feroze F, Schober MS, Yao F, Wood C, Puravs E, et al. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 2001;1:1327-38.
52. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004;145:3913-24. (Pubitemid 39037580)
53. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27: 380-92. (Pubitemid 47126935)
54. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009;138:245-56.
55. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 2011;30:2719-33.